NLS pharma-clinical-trial-box

Ultimovacs has announced that cemiplimab (Libtayo) will be used as the PD-1 checkpoint inhibitor in combination with UV1 in the Phase II randomized LUNGVAC trial rather than pembrolizumab (Keytruda). The move, which will be implemented January 1, 2023, follows the decision by the Norwegian Health Authorities of reimbursement of cemiplimab for monotherapy or first-line treatment […]

Mendus has presented survival data based on the completed active study period and long-term follow-up to date from the ADVANCE II clinical trial at the American Society of Hematology Annual Meeting. ADVANCE II is a Phase 2 monotherapy trial evaluating DCP-001 as a maintenance therapy in acute myeloid leukemia (AML) for patients brought into complete […]

IRLAB Therapeutics has announced that the final patient has completed the treatment period and follow-up visit in the Phase IIb study of mesdopetam in levodopa-induced dyskinesia in people with Parkinson’s disease (PD-LIDs). The top-line results are expected to be reported in mid-January 2023, states the company in a press release. An oral dopamine D3 antagonist […]

Evaxion Biotech has announced clinical data from the first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. The company reported encouraging interim safety and immunogenicity data from the Phase 1/2a study of its […]

EpiEndo Pharmaceuticals has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide or ‘Barriolide,’ with reduced antimicrobial resistance potential, which aims to address the unmet medical need for a treatment for COPD. “This is the first time […]

Affibody’s licensee Rallybio Corporation has announced positive topline results from a Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. In the ongoing Phase 1 study, all study participants that were administered a single 1 mL subcutaneous injection of 100 mg of RLYB116 (n=6) demonstrated a reduction in free C5 greater than […]